Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by Analysts

Key Points

• Janux Therapeutics, Inc. (NASDAQ:JANX) has received an average rating of "Buy" from analysts, with 13 out of 16 brokerages recommending a buy and an average 12-month price objective of $78.31.
• The company's shares have seen institutional investment growth, with 75.39% of its stock owned by hedge funds and other institutional investors.
• Janux reported a quarterly loss of ($0.55) earnings per share, missing analysts' estimates, and expects a projected earnings per share of ($1.38) for the current fiscal year.

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned an average rating of "Buy" from the sixteen brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $78.3077.

Several research analysts recently issued reports on JANX shares. Truist Financial started coverage on Janux Therapeutics in a research report on Wednesday, September 10th. They set a "buy" rating and a $100.00 price objective for the company. Barclays started coverage on Janux Therapeutics in a research report on Wednesday, September 17th. They set an "overweight" rating and a $47.00 price objective for the company. Stifel Nicolaus restated a "buy" rating and set a $45.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Raymond James Financial started coverage on Janux Therapeutics in a research report on Friday, July 11th. They set an "outperform" rating and a $65.00 price objective for the company. Finally, Piper Sandler started coverage on Janux Therapeutics in a research report on Monday, August 18th. They set an "overweight" rating and a $42.00 price objective for the company.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of JANX. California State Teachers Retirement System grew its stake in shares of Janux Therapeutics by 1.1% during the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company's stock valued at $858,000 after buying an additional 404 shares during the period. Avanza Fonder AB grew its stake in shares of Janux Therapeutics by 17.0% during the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company's stock valued at $86,000 after buying an additional 444 shares during the period. New York State Common Retirement Fund grew its stake in shares of Janux Therapeutics by 3.0% during the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company's stock valued at $444,000 after buying an additional 471 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Janux Therapeutics by 20.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company's stock valued at $109,000 after buying an additional 686 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Janux Therapeutics by 6.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,855 shares of the company's stock valued at $320,000 after buying an additional 727 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Trading Up 6.7%

JANX stock opened at $23.23 on Monday. The firm has a 50 day moving average of $24.07 and a 200-day moving average of $25.75. Janux Therapeutics has a 12-month low of $21.73 and a 12-month high of $71.71. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -12.91 and a beta of 2.84.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). Sell-side analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.